Roku (Nasdaq: ROKU), the #1 TV streaming platform in the U.S., Canada, and Mexico, and DoorDash (NYSE: DASH), the local commerce platform, announced a multi-year partnership to build a better TV experience and unlock new ways for consumers to access their favorite restaurants and more. The partnership includes:
According to internal Roku research, 1 in 3 Roku users order take-out or food delivery weekly. Furthermore, 36% of Roku users are interested in receiving interactive offers including a scannable QR code or text message. “Streaming and delivery just go together, which is why we're making it easier than ever for Roku users to order their favorite food right from their TV,” said Gidon Katz, President, Consumer Experience, Roku. “Just in time for the Big Game, we’re bringing consumers and marketers the same leading scale, data, and tech that have made buying a new device or signing up for a service simple and delightful.” DoorDash merchant partners can run ads directly on Roku. Consumers simply interact with the TV ad offer, receive the promotion through SMS/email, and are led to the storefront directly in the DoorDash app to redeem. With this integration, brands can easily track and measure ROI from beginning to end. “We are thrilled to partner with Roku on this unique partnership,” said Rob Edell, GM & Head of Consumer Engagement, DoorDash. “While this offer unlocks DashPass benefits and perks for Roku users everywhere, it also provides our merchant partners with an opportunity to promote DoorDash offers through TV streaming. Consumers can conveniently and affordably get the best of their neighborhood delivered to their door, while brands can reach diners at the right time and drive instant conversion from the comfort of the living room.” Source: Roku, Inc.
0 Comments
Durum Carbon LP offers exposure to rapidly growing carbon credit asset class Durum Capital Inc. today announced the launch of Durum Carbon LP, an investment vehicle created to provide financial exposure to global climate change policies while capturing the demands of environmentally conscious investors today. Canada’s transition to a low-carbon economy and tightening environmental regulations have led to the creation of a unique market opportunity for the purchase and sale of carbon credits in Canada. Durum Carbon LP ultimately seeks to participate in this market through the strategic acquisition and management of a carbon credit portfolio. What are carbon credits and how do they work? Climate change has become an increasingly important issue for many investors around the globe. Many governments around the world have implemented policies to incentivize heavy emitters to reduce greenhouse gas (“GHG”) output in an effort to slow the climate change trend. Putting a price on carbon is widely recognized as one of the most efficient means to reduce GHG emissions while also driving innovation. A carbon credit system is a market-based mechanism that incentivizes organizations to reduce overall emissions through the buying and selling of “carbon credits.” Carbon credits are tradable certificates that allow the holder to emit one tonne of carbon dioxide equivalent (“CO2e”) for each carbon credit utilized. For a visual comparison, one carbon credit would equal the carbon dioxide output of approximately 500 fire extinguishers combined. The cost of these emissions is equal to the cost of carbon credits in the market. As environmental regulations continue to tighten, it is expected that the value of carbon credits will increase, further raising the cost of GHG emissions. Canada’s transition to a low-carbon economy, tightening environmental regulations, and ambitious emission reduction goals by corporations are expected to increase the demand and value for carbon credits over the decade. Alberta’s Compliance Carbon Market A carbon credit is created in one of two ways:
These carbon credits can then be sold to and utilized by emitters in the marketplace that exceed their allowable emissions threshold. The purchase of carbon credits will allow the emitter to achieve compliance with environmental regulations and avoid paying a penalty in the form of the TIER Fund Credit price or carbon price. Carbon credits trade over the counter and are typically priced at a discount to the prevailing government mandated carbon price, currently set at $50/tCO2e. Durum Carbon LP strategy The Government of Canada has proposed an increase in the carbon price of $15/tCO2e each year until 2030. From the current level of $50/tCO2e, this equates to an increase of 240%. In a market known for its opaqueness and complexity, Durum Carbon LP’s strategy is a novelty in that it is both transparent and simple. Durum Carbon LP will purchase over-the-counter carbon credits, hold them and then sell them at a premium as the carbon price appreciates and when return targets are met. Management will actively monitor international compliance and voluntary markets to assess arbitrage opportunities and/or rebalance the carbon credit portfolio as global carbon markets mature. Through Durum Carbon LP, investors gain unique exposure to the rapidly growing asset class of carbon credits. The importance of strong governance in an emerging asset class
Climate change and associated carbon markets have garnered the interests of some of the most influential organizations in the world: governments, insurance agencies, pension plans and even central banks. With that type of attention, there will inevitably be a variety of different carbon-related investment opportunities on the horizon. While Durum Carbon LP’s investment strategy is simple, the execution may not be. It is important to understand the different types of carbon credits and evolving policies governing the many different carbon markets around the globe today. Durum Carbon LP is a listed entity on the Alberta Carbon Registry and currently purchases carbon credits under Alberta’s Technology Innovation and Emissions Reductions (TIER) regulatory framework. Durum Carbon LP’s strong governance, robust credit strategy, extensive network and years of energy trading experience provides a competitive advantage in today’s thinly traded carbon market. For additional information on Durum Carbon LP, carbon credits, and this rapidly growing asset class, please contact your authorized dealing representative. About Durum Carbon LP An investment vehicle created to provide investors with unique exposure to the rapidly growing asset class of carbon credits. Canada’s transition to a low-carbon economy and tightening environmental regulations have led to the creation of a unique market opportunity for the purchase and sale of carbon credits in Canada. Durum Carbon LP ultimately seeks to participate in this market through the strategic acquisition and management of a carbon credit portfolio. About Durum Capital Inc. Durum Capital Inc. is an asset manager focused on investments that require unique skills to uncover true value. Durum offers expertise in financing, governance, and operational efficiencies, ultimately creating alternatives to bring transparency to opaque situations in private markets. Source: Durum Capital Inc. Ceres Global Announces Letter of Intent to Acquire 50% Interest in Berthold Farmers Elevator, LLC3/15/2022 Ceres Global Ag Corp. (TSX: CRP) ("Ceres" or the "Corporation") a global agricultural, energy and industrial products merchandising and supply chain company, announced today that its wholly owned subsidiary, Riverland Ag Corp. ("Riverland"), has entered into a letter of intent to acquire Columbia Grain International's 50% membership interest in Berthold Farmers Elevator, LLC, a grain originator and merchandiser with locations in Berthold, N.D. and Carpio, N.D. ("BFE"). Riverland will pay cash for the investment, coming from working capital and available debt capacity. The other 50% membership interest in BFE is owned by Berthold Farmers Elevator Company ("BFEC"), a farmer cooperative also based in Berthold, N.D.
The letter of intent contains a binding purchase option exercisable by Riverland through April 29, 2022, by which date the transaction is expected to close. "Becoming a joint venture owner with Berthold Farmers Elevator Company advances our strategy to partner with growers and increase origination of our core products," said Mr. Robert Day, President and Chief Executive Officer at Ceres. "We look forward to connecting the hundreds of growers who make up the co-op in Berthold with Ceres and Riverland's customers and collaborating with all parties to bring solutions, starting from the farmgate and ending with consumers in the U.S. and internationally." "Adding Riverland as a joint venture partner in Berthold Farmers Elevator, LLC opens new and meaningful possibilities for our growers" said Aaron Haaland of BFE's board. "With Riverland and Ceres's expertise in managing railroad programs and providing destination market access, Berthold Farmers Elevator Company will be well positioned to serve the needs of its growers and patrons for decades to come." About Ceres Global Ag Corp. (ceresglobalagcorp.com) Ceres and its subsidiaries ("Ceres") add value across agricultural, energy and industrial supply chains through efficient sourcing, storing, transporting and marketing of high-quality agricultural commodities, value-added products and raw materials. Leveraging its network of commodity logistics centers and team of industry experts, Ceres connects farmers to customers around the world. Ceres is headquartered in Golden Valley, Minnesota, and together with its affiliated companies, operates 13 locations across Saskatchewan, Manitoba, Ontario, and Minnesota. These facilities have an aggregate grain and oilseed storage capacity of approximately 31 million bushels. Ceres has a 50% interest in Savage Riverport, LLC (a joint venture with Consolidated Grain and Barge Co.), a 50% interest in Farmers Grain, LLC (a joint venture with Farmer's Cooperative Grain and Seed Association), a 50% interest in Gateway Energy Terminal (an unincorporated joint venture with Steel Reef Infrastructure Corp.), a 25% interest in Stewart Southern Railway Inc. (a short-line railway located in southeast Saskatchewan with a range of 130 kilometers), and a 17% interest in Canterra Seed Holdings Ltd. (a Canada-based seed development company). About Berthold Farmers Elevator, LLC (www.bertholdfarmers.com) Established in 2002, BFE provides grain merchandising and storage services to over 300 BFEC patrons and other growers across a 4-county area. For more information about Ceres, please visit www.ceresglobalagcorp.com Company Provides Update on Oilseeds Business Ceres Global Ag Corp. (TSX: CRP) today announced its financial and operating results for the quarter ended December 31, 2021. All amounts are in U.S. currency unless otherwise noted. Second Quarter Highlights (Comparisons to second quarter of fiscal year 2021)
CEO Commentary “A strong second quarter capped the best six-month period in Ceres’ history,” said Robert Day, President and Chief Executive Officer of Ceres. “Despite smaller crops and lower inventories across the industry, we continued to find needed supply for key customers and consistently delivered high quality product on time. Key to our success again this quarter was our solid operational execution and strategic positioning ahead of the 2021 crop year. As a result, we achieved higher net trading margins, higher gross profit and a much-improved bottom line. Contributing to our positive results was our recently expanded soybean crush plant in Jordan, Manitoba, which ran at full capacity during the quarter and produced the best financial results in the plant’s history.” Outlook Mr. Day continued, “We believe grain prices are at or near levels at which demand will continue to be rationed in order to balance limited supply for the remainder of the crop year. Opportunities in the third quarter will continue to present themselves through effective trading and positioning; however, we expect that generating gross margins will become more challenging as inventories continue to diminish.” “Our plans to build an integrated canola processing facility in Northgate, Saskatchewan, remain on track to begin operations in the summer of 2024. The facility will have capacity to process approximately one million metric tons of canola and refine over 500 thousand metric tons of canola oil, for both food and renewable fuel, annually. We have engaged project management and design firms to develop the construction and design for the project, and we continue to make progress around equity partnership and funding.” In its second quarter Management Discussion and Analysis, dated February 9, 2022, Ceres Global Ag provided the following update on its plans to build to build a $350 million integrated canola processing facility in Northgate, Saskatchewan: Regarding growth and development, on May 25, 2021 Ceres announced its plan to build an integrated canola processing facility in Northgate, Saskatchewan, to help meet the current and growing global demand for canola products. The state‐of‐the‐art facility will have capacity to process approximately 1 million metric tons of canola and refine over 500 thousand metric tons of canola oil, for both food and renewable fuel, annually. The Corporation has engaged project management and engineering design firms to develop construction and design plans for the project, which are expected to be finalized late in the third quarter, or early in the fourth quarter of fiscal year 2022. In addition, during the quarter ended December 31, 2021, the Corporation made $10.8 million in deposits and commitments with major equipment suppliers as well as other consulting and engineering fees, which were critical to maintaining the project’s timeline. The facility is expected break ground this year and is targeted to be operational by summer 2024 and will create over 50 full time jobs in Saskatchewan, which is the largest canola producing province in Canada. The Corporation also hired Ascendant Partners, Inc. as an advisor and continues to explore financing options and arrangements with industry partners relating to the project. About Ceres Global Ag Corp.
Ceres and its subsidiaries add value across agricultural, energy and industrial supply chains through efficient sourcing, storing, transporting and marketing of high-quality agricultural commodities, value-added products and raw materials. Leveraging its network of commodity logistics centers and team of industry experts, Ceres connects farmers to customers around the world. Ceres is headquartered in Minneapolis, Minnesota, and together with its affiliated companies, operates 13 locations across Saskatchewan, Manitoba, Ontario, and Minnesota. These facilities have an aggregate grain and oilseed storage capacity of approximately 31 million bushels. Ceres has a 50% interest in Savage Riverport, LLC (a joint venture with Consolidated Grain and Barge Co.), a 50% interest in Farmers Grain, LLC (a joint venture with Farmer’s Cooperative Grain and Seed Association), a 50% in Gateway Energy Terminal (an unincorporated joint venture with Steel Reef Infrastructure Corp.), a 25% interest in Stewart Southern Railway Inc. (a short-line railway located in southeast Saskatchewan with a range of 130 kilometers), and a 17% interest in Canterra Seed Holdings Ltd. (a Canada-based seed development company). Source: Ceres Global Ag Corp. Ceres provides update on Northgate canola crush plant project
Ceres Global Ag Corp. (TSX: CRP) ("Ceres" or the "Corporation") today announced its financial and operating results for its first quarter ended September 30, 2021. All dollar amounts are in U.S. currency unless otherwise noted. First Quarter Highlights:
"A very strong first quarter has Ceres off to an excellent start to our fiscal year. Diversification over the past few years, relentless focus on our customers, and our ability to successfully navigate through a generational drought and volatile grain markets contributed to our strongest quarter on record," said Robert Day, President and Chief Executive Officer of Ceres. "In addition to the record financial performance, we made significant progress on our growth and development; specifically, advancing the transformational canola crush project that was announced in May 2021." "Meanwhile, we continue to make steady progress on plans to build a one million metric ton integrated canola processing facility in Northgate, Saskatchewan. We have made deposits with major equipment suppliers, continued our progress on design and engineering, and will shortly begin to evaluate proposals from potential strategic partners." For more details on Ceres' plans to build an integrated canola crush facility in Northgate, Saskatchewan, click here. Source: Ceres Global Ag Corp. Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan®/Reeqonus™11/12/2021 Infectious disease-focused biopharmaceutical company, Appili Therapeutics Inc., today announced that the Phase 3 PRESECO clinical trial evaluating oral antiviral Avigan®/Reeqonus™(favipiravir) for the treatment of mild-to-moderate COVID-19 did not achieve statistical significance on the primary endpoint of time to sustained clinical recovery. Additional analyses of the trial data are ongoing. The clinical trial enrolled 1,231 patients with mild-to-moderate COVID-19 from 38 study sites across the United States, Mexico, and Brazil.
“While we are disappointed by the topline results of the PRESECO trial, we remain steadfast in our belief that safe and effective oral antivirals are urgently needed for patients who are still struggling to overcome COVID-19. We wish to thank all the patients who participated, and hope that information obtained from our trial can help guide research and development around more potential treatment options for COVID-19,” said Dr. Armand Balboni, Chief Executive Officer, Appili Therapeutics. “Appili remains committed to addressing the challenges posed by infectious diseases and we will continue developing our pipeline to improve patient lives around the world.” The Phase 3 PRESECO (PREventing SEvere COVID-19 Disease) study is a double-blind, placebo-controlled, randomized, multi-center, global superiority trial investigating the safety and efficacy of oral Avigan/Reeqonus in the early treatment for adults infected with COVID-19 and showing mild-to-moderate symptoms. Participants were enrolled at multiple clinical trial sites in the United States, Brazil and Mexico. Participants were outpatients with mild-to-moderate symptoms who have had a recent positive COVID-19 test (within 72 hours of enrollment). Participants self-administered the drug regimen in their homes, with clinical investigators monitoring patients remotely. Avigan/Reeqonus is a broad-spectrum antiviral in oral tablet form. It is a selective inhibitor of viral RNA-dependent RNA polymerase (RdRP) with potent antiviral activity against single-stranded RNA viruses, including coronaviruses. Developed by FUJIFILM Toyama Chemical Co., Ltd. (FFTC) and approved in Japan as a treatment and stockpile countermeasure for pandemic influenza. Unlike most other interventions that researchers are evaluating in COVID-19, Avigan/Reeqonus has already been thoroughly studied in human trials and has a well-known safety profile, with over 3,000 subjects receiving at least one dose of the drug. Avigan/Reeqonus’ oral tablet form is shelf-stable and has an established commercial manufacturing process, which may provide advantages over other COVID-19 interventions, which often require temperature-controlled storage and/or injection or intravenous administration. Source: Appili Therapeutics Inc. DRI Healthcare Trust Doubles Quarterly Distribution to Unitholders Following Third Quarter Results11/8/2021 DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI" or "the Trust") today announced its results for the quarter ended September 30, 2021.
"We had a very active third quarter, executing multiple transactions and demonstrating our commitment and ability to build our cash flows and asset base," said Behzad Khosrowshahi, Chief Executive Officer of DRI Healthcare Trust. "Our existing assets continued to perform well during the quarter, and our recent transactions contribute meaningfully to our objective of generating sustainable growth in cash flow. We are pleased that this has allowed us to increase our quarterly distribution to unitholders." Third Quarter Highlights
Subsequent to Quarter End
Asset Performance During the third quarter, the Trust's portfolio included 17 royalty streams on 13 products that address medically necessary therapeutic areas, such as oncology, rare diseases, ophthalmology, endocrinology, autoimmune and vaccines. On September 30, 2021, the royalty asset portfolio had a book value, net of accumulated amortization, of US$306.6 million and generated Total Cash Royalty Receipts of US$15.4 million in the third quarter, on a pro forma basis. In addition, the Trust held a loan receivable with an outstanding gross principal balance of US$50.0 million at September 30, 2021. Liquidity and Capital On September 30, 2021, the Trust had cash on hand of US$33.8 million and an additional US$7.4 million funds held in trust. The Trust's secured notes had an outstanding balance of US$47.1 million on September 30, 2021, which was subsequently reduced with a principal payment of US$4.2 million made on October 15, 2021 from the funds held in trust, following which the remaining balance in funds held in trust was released to the Trust. On October 22, 2021 the remaining secured notes were fully retired using proceeds of a new credit facility as described below. The Trust had units outstanding of 40,107,407 on September 30, 2021, all of which were issued in connection with the IPO and concurrent private placement on February 19, 2021. On September 30, 2021, the Trust was granted approval by the Toronto Stock Exchange for the proposal to acquire, from time to time, if considered advisable, up to 1,500,000 units of the Trust for cancellation between October 5, 2021 and October 4, 2022. As at November 1, 2021, the Trust had acquired 70,152 units at an average unit price of US$6.64. About DRI Healthcare Trust DRI Healthcare Trust provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Our business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties with the aim to deliver attractive growth in cash royalty receipts over the long term. DRI Healthcare Trust is an unincorporated open-ended trust governed by the laws of the Province of Ontario, externally managed by its manager, DRI Capital Inc. DRI Healthcare Trust's units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol "DHT.UN" and in U.S. dollars under the symbol "DHT.U". Source: DRI Healthcare Trust Study expected to include patients with top priority COVID-19 variants, including Delta
Infectious disease company, Appili Therapeutics (TSX: APLI; OTCQX: APLIF), has completed enrollment in its global Phase 3 PRESECO (PREventing SEvere COVID-19) trial evaluating Avigan®/Reeqonus™(favipiravir) as an oral treatment for COVID-19. Appili expects to report top-line data from this trial in approximately 60 days. With today’s announcement, the double-blind, placebo-controlled, randomized, global, multi-center trial has enrolled 1,231 patients from 38 study sites across the United States, Mexico, and Brazil. “Completing enrollment in this large Phase 3 pivotal trial in just ten months is a tremendous accomplishment for Appili. With this major milestone now achieved, we have a clear path to completing the PRESECO data analysis in the coming weeks and determining if Avigan/Reeqonus has the potential to meet the urgent global clinical need for a safe and effective oral treatment for this deadly disease,” said Armand Balboni, M.D., Ph.D., Chief Executive Officer, Appili Therapeutics. The primary goal of PRESECO is to evaluate the impact of oral Avigan/Reeqonus on time to COVID-19 symptom resolution. The study also aims to evaluate the effect of oral treatment on progression to more severe COVID-19 disease. Finally, this Phase 3 clinical trial includes a viral shedding sub-study, which is evaluating impact of the treatment on time to viral clearance. Viral isolates will also be sequenced for identification of COVID-19 variants. “As we have seen over the past 18 months, this virus continues to mutate, enhancing its ability to infect and cause significant symptoms, especially in those who have not been vaccinated. My hope is that Avigan/Reeqonus will emerge as a standard of care treatment for mild to moderate COVID-19 patients, resolve patient’s symptoms more rapidly, and limit progression to more severe disease” said Yoav Golan, M.D., Chief Medical Officer, Appili Therapeutics. About the PRESECO Clinical Trial The Phase 3 PRESECO (PREventing SEvere COVID-19 Disease) study is a double-blind, placebo-controlled, randomized, multi-center, global superiority trial investigating the safety and efficacy of oral Avigan/Reeqonus in the early treatment for adults infected with COVID-19 and showing mild-to-moderate symptoms. Participants were enrolled at multiple clinical trial sites in the United States, Brazil and Mexico. Participants are outpatients with mild-to-moderate symptoms who have had a recent positive COVID-19 test (within 72 hours of enrollment). Participants self-administer the drug regimen in their homes, with clinical investigators monitoring patients remotely. About Avigan/Reeqonus Avigan/Reeqonus is a broad-spectrum antiviral in oral tablet form. It is a selective inhibitor of viral RNA-dependent RNA polymerase (RdRP) with potent antiviral activity against single-stranded RNA viruses, including coronaviruses. Developed by FUJIFILM Toyama Chemical Co., Ltd. (FFTC) and approved in Japan as a treatment and stockpile countermeasure for pandemic influenza. Unlike most other interventions that researchers are evaluating in COVID-19, Avigan/Reeqonus has already been thoroughly studied in human trials and has a well-known safety profile, with over 3,000 subjects receiving at least one dose of the drug. Avigan/Reeqonus’ oral tablet form is shelf-stable and has an established commercial manufacturing process, which may provide advantages over other COVID-19 interventions, which often require temperature-controlled storage and/or injection or intravenous administration. Appili has joined a consortium of companies, including Dr. Reddy’s Laboratories, Global Response Aid, and FFTC, for the worldwide development and distribution of Avigan/Reeqonus tablets for the potential treatment and prevention of COVID-19 (excluding Japan, China, and Russia). This consortium is designed to ensure that Avigan/Reeqonus is thoroughly evaluated in rigorous clinical studies and, if it receives the proper regulatory approvals, has the infrastructure in place to support worldwide manufacturing and distribution. Source: Appili Therapeutics Inc. Andean Precious Metals Launches 20,000 Metre Exploration Program and Commences Trading on the OTCQB9/22/2021 Established Latin American silver producer, Andean Precious Metals (TSX-V: APM, OTCQB: ANPMF), has launched a 20,000 metre, phase one exploration campaign focused on the company’s wholly-owned Rio Blanco and San Pablo projects in Bolivia. The mulit-project exploration program is being undertaken to extend the life-of-mine at Andean's flagship San Bartolomé project to ten years. Yesterday, the company also announced that its common shares commenced trading on the OTCQB Venture Market under the symbol “ANPMF”. “Since becoming a public company in March, our focus has been on expanding our existing resource and reserve base along with the scope and profitability of our third party ore purchasing business. We have made significant progress on both fronts and are now well positioned to advance an aggressive exploration campaign. Our portfolio of exploration assets includes two highly prospective gold projects that are within the operating envelope of San Bartolomé. We believe that the San Pablo and Rio Blanco Projects have the potential to create significant value for the shareholders of Andean, and we look forward to updating the market with drill results beginning in October.” - Simon Griffiths, President and CEO of Andean. Phase One Exploration Program Overview Andean Precious Metals controls a portfolio of exploration assets in Bolivia, of which the San Pablo and Rio Blanco Projects (“San Pablo” and “Rio Blanco”) are the most advanced. Both projects are located within the operating envelope of the San Bartolomé Mine, which is currently producing precious metals from six different locations in Bolivia. Rio Blanco and San Pablo are both bulk-tonnage, potentially surface-mineable targets and are being evaluated as synergistic with San Bartolomé. The Company plans to drill 10,000 metres at Rio Blanco and 10,000 metres at San Pablo. Currently, three diamond drill rigs are contracted and active. Once all assays are received from the Phase One exploration program, the Company expects to launch a Phase Two exploration program of an additional 20,000 metres. Both phases are fully funded. Contracts have this week been signed with Quantec for Titan geophysical surveys at both properties. Rio Blanco The 100% owned Rio Blanco Project comprises 13,462 hectares in the department of Potosi. Rio Blanco is located on an historic Au-Sb belt that hosts some of the most prolific mining districts in Bolivia, including Caracota, Chilcobija, Sucre, Candelaria, and Rosa de Oro. Rio Blanco is an Orogenic gold deposit hosted in a folded Ordovician sedimentary sequence composed of shales and sandstones that were affected by a low-grade metamorphism. Extensive geological mapping has been completed and 1500 samples assayed at ALS in Lima. The Phase One diamond drill program covers an initial 7km of a 22km long structural corridor along the axial plane of Rio Blanco anticline. This structural system hosts ore mineralisation in formal veins, stockworks, saddle reefs and lenticular bodies. Rio Blanco has extensive historical workings, including several placer gold deposits. Similar Au-Sb occurrences are well known around the world, such as Bendigo in Australia. Andean’s phase one drill program has 22 diamond drill holes planned which follow an extensive program of geological mapping and trenching perpendicular to the axis of the target mineralisation. San Pablo The 100% owned San Pablo Project comprises 650 hectares in the department of Potosi. San Pablo is located at the southern end of a prolific orogenic gold belt that hosts several of Bolivia’s largest deposits including the Kori Kollo gold mine (Newmont) which produced more than 5 million ounces and the San Bernadino Gold mine which produced over 2 million ounces ounces. The Company has completed initial exploration works including geological mapping, surface sampling and an initial diamond drill programme comprising twelve holes into four discrete targets which are within close proximity of each other. DDH results are expected to be released during October. Early work suggests gold-hosted mineralization occurs near surface in an intrusion-related gold system with narrow sheeted veins together with separate, more discrete veins. The presence of secondary biotite alteration may indicate the presence of porphyry-style mineralization on the property. The Company is planning to test for the presence of porphyry-style mineralization with its new exploration work. Quantec Geoscience's Titan 24 DCIP and magnetotelluric ("DCIP-MT") technology is being considered in a 17 line-kilometre survey. This programme is scheduled for the second half of October. Qualified Person The scientific and technical content disclosed in this press release was reviewed and approved by Donald J. Birak, A Qualified Person as defined by Canadian National Instrument 43-101, Registered Member, Society for Mining, Metallurgy and Exploration (SME), Fellow, Australasian Institute of Mining and Metallurgy (AusIMM). Source: Andean Precious Metals Corp. New Funds Will Help Expedite Completion of Recently Expanded Pivotal Phase 3 Study on Oral Antiviral Medicine
Infectious disease company, Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF), has entered into an agreement with FUJIFILM Toyama Chemical Co., Ltd. (“FFTC”), that will provide funding support for its Phase 3 PRESECO (PREventing SEvere COVID-19) clinical trial. The new funding of $1,000,000 USD was secured from FFTC, one of the Company’s partners in a global consortium focused on the worldwide development, commercialization, and distribution of Avigan®/Reeqonus™ (favipiravir) tablets for the potential treatment and prevention of COVID-19. The new funding will support various components of the recently expanded PRESECO trial, including study close-out activities as the Company prepares for database lock and top-line results. Enrollment targets for PRESECO and the viral shedding sub-study were recently increased to enable additional enrollment of COVID-19 variant cases and maximize the number of patients in the final analysis. As part of the agreement, FFTC will receive direct access to PRESECO data in support of local regulatory submissions in Japan. PRESECO is investigating the safety and efficacy of Avigan/Reeqonus in the early treatment outpatient setting for adults infected with COVID-19. “FFTC recognizes the unmet need of this pandemic, which is the lack of safe, effective oral antiviral medicines to treat mild-to-moderate COVID-19 patients. With FFTC’s support, we are one step closer to determining if Avigan/Reeqonus will meet this need,” said Dr. Armand Balboni, Chief Executive Officer, Appili Therapeutics. Avigan/Reeqonus is a broad-spectrum antiviral in oral tablet form. It is a selective inhibitor of viral RNA-dependent RNA polymerase (RdRP) with potent antiviral activity against single-stranded RNA viruses, including coronaviruses. Developed by FFTC and originally approved in Japan as a treatment for pandemic influenza, this product is one of the few oral antiviral candidates in Phase 3 clinical development to treat newly diagnosed COVID-19 patients. “We share the sense of urgency that so many physicians and nurses have expressed globally for the need of new treatments developed that will help bring this pandemic to an end. We remain confident Avigan/Reeqonus will play an important role in North America, Japan, and around the world in the treatment of COVID-19 now, and in the near future,” said Junji Okada, President, FUJIFILM Toyama Co., Ltd. About the PRESECO Clinical Trial The Phase 3 PRESECO (PREventing SEvere COVID-19 Disease) study is a double-blind, placebo-controlled, randomized, multi-center superiority trial investigating the safety and efficacy of Avigan/Reeqonus in the early treatment for adults infected with COVID-19 and showing mild-to-moderate symptoms. Investigators are enrolling participants at multiple clinical trial sites in the United States, Brazil and Mexico. Participants are outpatients with mild-to-moderate symptoms who have had a recent positive COVID-19 test (within 72 hours of enrollment). Participants self-administer the drug regimen in their homes, with clinical investigators monitoring patients remotely. About Avigan/Reeqonus Avigan/Reeqonus is a broad-spectrum antiviral in oral tablet form. It is a selective inhibitor of viral RNA-dependent RNA polymerase (RdRP) with potent antiviral activity against single-stranded RNA viruses, including coronaviruses. Developed by FUJIFILM Toyama Chemical Co., Ltd. (FFTC) and approved in Japan as a treatment and stockpile countermeasure for pandemic influenza. Unlike most other interventions that researchers are evaluating in COVID-19, Avigan/Reeqonus has already been thoroughly studied in human trials and has a well-known safety profile, with over 3,000 subjects receiving at least one dose of the drug. Avigan/Reeqonus’ oral tablet form is shelf-stable and has an established commercial manufacturing process, which may provide advantages over other COVID-19 interventions, which often require temperature-controlled storage and/or injection or intravenous administration. Source: Appili Therapeutics Inc. |
Follow @SharePitch on TwitterArchives
January 2024
Categories |